Diabetes Drug May Slow Parkinson's Disease
The type 2 diabetes drug exenatide (Bydureon, Byetta, AstraZeneca) has potential disease-modifying effects in Parkinson's disease, results of a randomized, double-blind, placebo-controlled trial suggest.
The type 2 diabetes drug exenatide (Bydureon, Byetta, AstraZeneca) has potential disease-modifying effects in Parkinson's disease, results of a randomized, double-blind, placebo-controlled trial suggest.